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Epigeneticmechanisms,actingviachromatinorganization,ﬁxintimeandspacediﬀerenttranscriptionalprogramsandcontribute
to the quality, stability, and heritability of cell-speciﬁc transcription programs. In the last years, great advances have been made in
our understanding of mechanisms by which this occurs in normal subjects. However, only a small part of the complete picture has
beenrevealed.Abnormalgeneexpressionpatternsareoftenimplicatedinthedevelopmentofdiﬀerentdiseases,andthusepigenetic
studies from patients promise to ﬁll an important lack of knowledge, deciphering aberrant molecular mechanisms at the basis of
pathogenesis and diseases progression. The identiﬁcation of epigenetic modiﬁcations that could be used as targets for therapeutic
interventions could be particularly timely in the light of pharmacologically reversion of pathological perturbations, avoiding
changes in DNA sequences. Here I discuss the available information on epigenetic mechanisms that, altered in neuromuscular
disorders, could contribute to the progression of the disease.
1.Introduction
Although every cell within our body bears the same genetic
information, only a small subset of genes is transcribed in
a given cell at a given time. The distinct gene expression of
genetically identical cells is responsible for cell phenotype
and depends on the epigenome, which involve all structural
levels of chromosome organization from DNA methylation
and histone modiﬁcations up to nuclear compartmentaliza-
tionofchromatin[1–5].Enormousprogressoverthelastfew
years in the ﬁeld of epigenetic regulation indicated that the
primary, monodimensional structure of genetic information
is insuﬃcient for a complete understanding of how the
networking among regulatory regions actually works. The
contribution of additional coding levels hidden in the three-
dimensional structure of the chromosome and nuclear
structures appears to be a fundamental aspect for the control
of the quality and stability of genetic programs. Damage
or perturbation of epigenetic components may lead to
deviations from a determined cellular program, resulting in
severe developmental disorders and tumour progression [6,
7]. Moreover, for human complex diseases, the phenotypic
diﬀerences and the severity of the disease observed among
patients could be attributable to inter-individual epigenomic
variation. Unravelling the intricacies of the epigenome will
be a complex process due to the enormity and dynamic
nature of the epigenomic landscape but is essential to gain
insights into the aetiology of complex diseases.
2. The Complexity of the Epigenome
The epigenome consists of multiple mechanisms of tran-
scriptional regulation that establish distinct layers of genome
organizationandincludescovalentmodiﬁcationofDNAand
histones, packaging of DNA around nucleosomes, higher-
order chromatin interactions, and nuclear positioning [4].
The ﬁrst layer of epigenetic control is the DNA methylation,
an heritable epigenetic mark typically associated with a
repressed chromatin state [8], which seems to play a role,
together with other histone modiﬁcations, in preventing
gene reactivation [9]. Vertebrate genomes are predominantly
methylatedatcytosineofthedinucleotidesequenceCpG(for
ar e v i e ws e e[ 3]). Despite the high level of CpG methylation,
some regions of mammalian genomes are refractory to this
modiﬁcation[10].Theseregions,calledCpGislands,contain
high levels of CpG dinucleotides [11] and localize at or2 Comparative and Functional Genomics
near gene promoters [12], suggesting a strong correlation
betweendiﬀerentialmethylationofCpGislandsandﬂanking
promoter activity. From the mechanistic point of view, DNA
methylation can inhibit gene expression by blocking the
access of transcriptional activators to their binding site on
DNAorbyrecruitingchromatinmodifyingactivitiestoDNA
(for a review see [3]). For long time, DNA methylation was
considered as a stable epigenetic mark. However, recently it
hasbeenshownthatmethylatedcytosinescouldbeconverted
to 5-hydroxymethylcytosines (5hmeC) by Tet (Ten eleven
Translocation) family proteins [13–15] and the generation
of 5hmeC is a necessary intermediate step preceding active
demethylation of DNA [16]. The second level of epigenetic
regulation occurs through posttranslational histone mod-
iﬁcation. Histone proteins assemble into a complex that
associates with DNA forming the elementary unit of chro-
matin packaging: the nucleosome. The amino and carboxy
termini of the histones (histone tails), protruding from the
nucleosome,playanessentialroleincontrollinggeneexpres-
sion, being the target for posttranscriptional modiﬁcations,
including acetylation, methylation, phosphorylation, ubiq-
uitylation, biotinylation, and several others (for a review see
[2, 17]). Multiple histone modiﬁcations can also coexist on
the same tail, dictating speciﬁc biological readouts [18–24].
In addition to histone modiﬁcations, a fraction of chromatin
contains one or more variant isoforms of the canonical
histones that can be incorporated into speciﬁc regions of
the genome throughout the cell cycle and are essential for
the epigenetic control of gene expression and other cellular
responses (for a review see [25]). Combinatorial histone
modiﬁcations and variants play an important role in folding
nucleosomal arrays into higher-order chromatin structures,
creating local structural and functional diversity and delim-
iting chromatin subdomains then subjected to a speciﬁc
protein environment. Chromatin higher-order structures
established at DNA level give signals that are recognized by
speciﬁc binding proteins that in turn inﬂuence gene expres-
sion and other chromatin functions [1, 26]. This represents
anadditionallayerofepigeneticgeneregulationandincludes
factors, such as transcriptional repressors or activators, that
recognizing speciﬁc chromatin patterns regulate the folding
or modulate the activity of RNA Polymerase II (Pol II).
The topological organization of chromatin and the asso-
ciation of regulatory elements with speciﬁc components of
the eukaryotic nucleus is another parameter to be considered
in the complexity of the epigenetic information. It is now
clear that speciﬁc chromosomal conformations, mediated by
cis-trans interactions, are associated with distinct transcrip-
tional states in many organisms, allowing the establishment
o fc h r o m a t i nb o u n d a r i e sb e t w e e np r o m o t e r sa n dr e g u l a t o r y
element (for a review see [27, 28]). The nuclear localization
also inﬂuences gene expression, regulating its access to
speciﬁc machinery responsible for speciﬁc functions, such
as transcription or replication [29, 30]. In addition, due
to its highly dynamic nature, the genome moves in the
nucleus driving speciﬁc genomic regions toward nuclear
compartments deﬁned by a high concentration of speciﬁc
factors and substrates that facilitate more eﬃcient biological
reactions [31]. This constant motion plays also a role in
coordinating the expression of coregulated genes, separated
by longer chromosomal regions or located on diﬀerent
chromosomes [32].
The evolutionarily conserved Polycomb group of pro-
teins (PcG) are multiprotein complexes that play a cen-
tral role during development [1]. The most characterized
PcG-encoded protein complexes are Polycomb Repressive
Complex 1 (PRC1) and 2 (PRC2). Three other complexes
were characterized in Drosophila, PHO-repressive complex
(PhoRC), dRing-associated factors (dRAF) complex, and
Polycomb repressive deubiquitinase (PR-DUB), and their
components have orthologues in mammals [33, 34]. PcG
complexes mediate gene silencing by regulating diﬀerent
levels of chromatin structures. Biochemical studies revealed
that Enhancer of zeste 2 (EZH2), the Histone Methyl
Transferase (HMTase) subunit of PRC2, marks lysine 27 of
histone H3 [35–38] and PRC1 complex monoubiquitylates
Lys119ofhistoneH2A[39].Moreover,theH3K27me3mark
constitutes a docking site for the chromodomain present in
PRC1 components [35], determining a sequential recruit-
mentofPRCcomplexes,althoughrecentchromatinproﬁling
studies evidenced that PRC1 and PRC2 also have targets
independent of each other [40, 41]. Examination of the
localization of PcG proteins in the nucleus has revealed that
they are organized into distinct domains called Polycomb or
PcG bodies, which are often localized, closed to pericentric
heterochromatin [42]. PcG targets are frequently localized in
PcG bodies in the tissue where they are repressed, suggesting
that such nuclear localization may be required for eﬃcient
silencing [43, 44]. However, the number of PcG bodies is less
than the number of PcG target genes, implying that several
PcG targets share the same body. FISH studies together with
Chromosome Conformation Capture (3C) analysis have
conﬁrmed this coassociation [43–46] and revealed that PcG-
dependent higher-order structures organization is conserved
in mammals [47–49]. The characteristic feature of the PcG
memory system is inheritability of gene expression patterns
throughout the cell cycle, ensured by the PcG capability to
bind its own methylation mark [50, 51] and speciﬁc cell
cycle-dependent dynamics [52–55]. Besides their extensively
described role in development, in the last years emerging
evidence has shown PcG involvement in several other
biologicalprocesses,suchasXchromosomeinactivation,dif-
ferentiation, and reprogramming (reviewed in [56–58]). The
highly variability of PcG functions and the ﬁne quantitative
and qualitative tuning of their activities is generated by the
association of diﬀerent PcG proteins and their coregulators
in a combinatorial fashion and/or by the regulation of
their recruitment at speciﬁc chromatin sites (reviewed in
[1, 59, 60]). One recent example is a genomewide study
of TET complex localization, in murine Embryonic Stem
(ES) cells. This complex, responsible for 5hmeC generation,
colocalizes with a subpopulation of Polycomb-repressed
genes, contributing to gene transcription control [61–63].
3. MuscleDiseases
Skeletal muscles are composed by multiple aligned multinu-
cleated cells, the myoﬁbers, wrapped in a plasma membraneComparative and Functional Genomics 3
calledsarcolemma.Insidethesarcolemmaandallaroundthe
myoﬁbers, there is a specialized cytoplasm, the sarcoplasm,
that contains the usual subcellular elements [64]. A plethora
of structural molecules and cellular proteins connecting all
the ﬁbers components together with specialized signalling
pathways and transcription factors are required for a correct
muscle formation and function. Dysfunction or lack of
any component of the skeletal muscle could lead to a
muscular disorder, the muscular dystrophy (MD), clini-
cally characterized by muscle weakness and skeletal muscle
degeneration [64]. Some dystrophies arise from mutations
of molecules that play a role outside the nucleus while other
dystrophies derive from dysfunction of the nucleus or its
membrane. The nonnuclear dystrophies include Duchenne
MD (DMD), Becker MD (BMD), and all MD aﬀecting
proteins working in the sarcoplasm. DMD is the most severe
form of muscular dystrophy and is caused by mutations that
preclude the production of the essential cytoskeletal muscle
proteindystrophin,whichanchorsproteinsfromtheinternal
cytoskeleton to a complex of proteins (dystrophin-associated
protein complex, DAPC) on the membrane of muscle
ﬁbers [65]. This interaction is important for the structural
stabilization of the sarcolemma [66]. Interestingly, recent
reports highlighted the inﬂuence of epigenetic mechanisms
regulating histone deacetylation (HDAC) pathways in the
development of this disease [67–69] and the reversion of
some DMD-associated phenotypes in presence of inhibitors
of HDACs [70, 71].
The nuclear dystrophies include all MD generated by
a dysfunction of nuclear membrane (laminopathies) or
by expansion or contraction of nucleotide repeats, not
necessarilycontainedinacodingregion,whichaﬀectnuclear
function. Myotonic dystrophy is the most common MD
in adult and is a complex multisystemic inherited muscle
degenerative disorder caused by a pathogenic expansion
of microsatellite repeats within noncoding elements of
dystrophia myotonica protein kinase (DMPK) or zinc ﬁnger
protein 9 (ZNF9)g e n e s[ 72]. These expansions, although
transcribed into RNA, do not aﬀect the protein-coding
region of any other gene. However, it has been shown that
transcripts accumulate in the nucleus and interfere with
protein families that regulate alternative splicing during
development [64, 73]. In this paper, I will describe the con-
tribution of epigenetic mechanisms mediated by Polycomb
group of proteins to two human nuclear muscular dys-
trophies, facioscapulohumeral muscular dystrophy (FSHD),
and laminopathies.
4.Polycomb GroupofProteinasEpigenetic
Regulators of Muscle Differentiation
PcG proteins regulate large numbers of target genes, primar-
ily those involved in diﬀerentiation and development [74–
80]. During cell diﬀerentiation the progressive restriction
of the developmental potential and increased structural and
functional specialization of cells ensure the formation of
tissues and organs [57]. Myogenesis is a multistep process
that starts with the commitment of multipotent mesodermal
precursor cells. Upon appropriate stimuli these cells diﬀer-
entiate and fuse into multinucleated myotubes, giving rise
to the myoﬁbers. In mammals, PcG proteins are primarily
involved in muscle diﬀerentiation by binding and repressing
muscle-speciﬁc gene regulatory regions in undiﬀerentiated
myoblasts to prevent premature transcription. During myo-
genesis progression, PcG binding and H3K27me3 are lost
at muscle-speciﬁc loci, resulting in appropriate muscle gene
expression [81–84]. Interestingly, artiﬁcial modulation of
EZH2 levels, either by depletion or overexpression, consis-
tently aﬀects normal muscle diﬀerentiation, accelerating or
delaying, respectively, muscle cell fate determination [82, 83,
85]. Although emerging evidence suggested a key role for
epigenetic mechanisms in muscular diseases [68, 71, 86–
89], the precise contribution of Polycomb proteins to the
pathology and progression remains largely unexplored.
5. Facioscapulohumeral Muscular
Dystrophy (FSHD)
Facioscapulohumeral muscular dystrophy (FSHD) is a fre-
quent (1:15.000) dominant autosomal miopathy that is
characterizedbyprogressive,oftenasymmetricweaknessand
wasting of facial (facio), shoulder, and upper arm (scapu-
lohumeral) muscles [90]. Monozygotic twins with diﬀerent
penetrance of FSHD have been described, suggesting a
strong epigenetic contribution to the pathology [91, 92].
Genetically, FSHD1, one of the two forms of FSHD, is
caused by a contraction of the highly polymorphic D4Z4
macrosatellite repeat in chromosome 4q [93]. In the general
population, this repeat array varies between 11 and 100 units
of 3,3kb each, ordered head to tail [94]. Most patients with
FSHD1 present a partial deletion of the D4Z4 array, which
leaves1–10unitsontheaﬀectedallele[93].Althoughalinear
negative correlation between repeat size and clinical severity
has not been observed, some ﬁndings indicated that smaller
D4Z4 arrays result in earlier disease onset and enhanced
severity in patients [95–97]. Interestingly, at least one D4Z4
unit is necessary to develop FSHD, as monosomy of 4q does
not cause the disease [98]. In addition to polymorphism
associated with D4Z4 repeat number, two allelic variants
of the 4q subtelomere, termed 4qA and 4qB, have been
identiﬁed. These variants diﬀer for the presence of a β
satellite repeat immediately distal to the D4Z4 array on
4qA allele [99]. Whereas 4qA and 4qB chromosomes are
almost equally common in the population, FSHD arises
mainly from 4qA haplotype [99–102]. D4Z4 repeat arrays
are not restricted to chromosome 4q, but homologous
sequenceshavebeenidentiﬁedonmanychromosomes[103].
In particular, the subtelomere of chromosome 10q is almost
identical to the region in 4q containing D4Z4 repeats,
containing highly homologous and equally polymorphic
repeat arrays [104, 105]. However, chromosome 10 with
less than 11 repeat units does not cause FSHD1 [106],
suggesting that the chromatin environment associated with
chromosome 4q and/or 4q-speciﬁc DNA sequences could
contribute to FSHD development. In agreement with this
observation, the relatively gene-poor region ﬂanking D4Z44 Comparative and Functional Genomics
repeats on chromosome 4q contains two attractive candi-
dates that have been characterized for their contribution
to disease development: FRG1 (FSHD Region Gene 1) and
the double-homeobox transcription factor DUX4. FRG1 is
highly conserved in both vertebrates and invertebrates and
it has been found overexpressed in some FSHD samples
[107, 108]. Moreover, transgenic mice overexpressing FRG1
develop, selectively in the skeletal muscle, pathologies with
physiological, histological, ultrastructural, and molecular
features that mimic human FSHD [109]. However, FRG1
overexpression in FSHD samples is not a uniform ﬁnding
[110, 111] and thus the contribution of the FRG1 gene to the
FSHD phenotype needs further validation. Although some
evidence suggests a role for FRG1 in pre-mRNA splicing
[109, 112, 113], to date the mechanism of action and the
role of FRG1 in FSHD onset and development is largely
unknown.
Aberrant production of DUX4, the gene present in the
D4Z4 array, was detected in both FSHD1 and FSHD2 muscle
biopses [114], suggesting that D4Z4 could aﬀect disease
progression [115]. However, D4Z4 array has a complex
transcriptional proﬁle that includes sense and antisense
transcripts and RNA processing [116]. The DUX4 mRNA
is generated by transcription of the last, most distal, unit of
the array, including a region named pLAM, which contains
a polyadenylation signal, necessary for DUX4 transcript
stabilization [115]. The absence of this polyadenylation
signal on chromosome 10 suggests its involvement in
FSHD development [100]. The DUX4 pre-mRNA can be
alternatively spliced [116] and there has been found a
DUX4 mRNA isoform encoding for the full-length protein,
expressed in FSHD muscle, whereas healthy subjects present
an alternative splicing mRNA encoding for a truncated
protein [114].
DUX4 RNA and protein levels have been arguments
of debate in the ﬁeld for several years. Previous works
demonstrated a proapoptotic function for DUX4 [117]a n d
DUX4 overexpression was found to have dramatically toxic
eﬀect on cell growth [118]. On the other hand extremely
low levels of DUX4 were found in FSHD muscles raising
some doubts on the role of this gene in FSHD development
[114, 119]. In a recent report, overexpression of DUX4
mRNA in human primary myoblasts followed by gene
expression analysis showed deregulation of several genes
involved in RNA splicing and processing, immune response
pathways, and gametogenesis [119]. These genes were found
aberrantly expressed in both FSHD1 and FSHD2 muscles
while a partial recovery of the repressed state occurs upon
depletion of endogenous DUX4 mRNA. Although no direct
evidence was presented about the role of deregulated genes
in the FSHD development, theseﬁndings suggestthat critical
DUX4 protein and RNA levels could be responsible for gene
transcription deregulation in FSHD [119].
Aside putative genes involved in the FSHD development
there is a general consensus in the ﬁeld in supporting the
view that epigenetic mechanisms are important players in
FSHD, aﬀecting the severity of the disease, its rate in pro-
gression, and the distribution of muscle weakness [120, 121].
Increasing evidence suggested that, in patients, chromatin
conformation of FSHD locus is altered at multiple levels,
from DNA methylation up to higher-order chromosome
structures,resultinginperturbationofheterochromaticgene
silencing in the subtelomeric domain of the long arm of
chromosome 4. As stated previously, DNA methylation is
associated with gene silencing and defects in methylation
are generally associated with deregulation of transcriptional
programs and disease [6]. D4Z4 is overall very GC-rich,
having characteristics of CpG islands [122], and in healthy
subjects is methylated, while contracted D4Z4 is always
associated with an hypomethylation [123, 124]. Interest-
ingly, FSHD2 patients, which phenotypically show FSHD
though lacking D4Z4 contractions, display general D4Z4
hypomethylation [123], indicating an important epigenetic
condition necessary to develop or generate the disease.
Combination of posttranslation histone modiﬁcations
establishes a speciﬁc code that recruits nuclear factors
responsible of several functions such as transcriptional or
replication control. The D4Z4 repeat array is enriched of
two repressive marks: trimethylation of lysine 9 or 27 of
histone H3 (H3K9me3 and H3K27me3, resp.). The ﬁrst,
generally associated with constitutive heterochromatin, is
deposited by the histone methyltransferase SUV39 and is
responsibleforHP1repressorrecruitment[125].H3K27me3
is characteristic of facultative heterochromatin, is deposited
by the PRC2 subunit EZH2, and in turn recruits PRC1 and
PRC2 to establish transcriptionally repressed domains. It has
been shown that H3K27me3 and the two Polycomb proteins
YY1 and EZH2 are bound to D4Z4 and FRG1 promoter in
myoblasts [107, 108] and are reduced during myogenic dif-
ferentiation [108]. Interestingly, DNA association studies, by
using 3C technologies [126], revealed that D4Z4 physically
interacts with FRG1 promoter and this DNA loop is reduced
upon diﬀerentiation. These epigenetic signatures dynamics
during myogenesis are accompanied by a gradual upreg-
u l a t i o no fF R G 1[ 108]. Conversely, in FSHD1 myoblasts
the D4Z4-FRG1 promoter interaction is reduced and FRG1
expression is anticipated during diﬀerentiation, suggesting
an alteration of epigenetic signatures dynamics occurring
when the diﬀerentiation starts. Notably, H3K27me3 can still
be detected by ChIP at D4Z4 repeats in FSHD1 myoblasts,
although by 3D immuno-FISH it was found speciﬁcally
reduced on D4Z4 on 4q chromosome in FSHD1 myoblasts
compared with controls [108]. This apparent inconsistency
is justiﬁed by the extensive duplication of D4Z4 sequences
in the human genome and the limitation of ChIP assay to
distinguish speciﬁc 4q D4Z4 repeat. In addition to the com-
plex heterochromatic features found at D4Z4 locus, there
has been shown the presence of histone marks associated
with transcriptional activation in the ﬁrst proximal D4Z4
unit of the array, such as acetylation of histone H4 and di-
methylation of Lys 4 of histone H3 [110, 125]. This could
reﬂectthecomplexityofbidirectionaltranscriptionalactivity
at the locus and could suggest the potential presence of
noncoding RNA that further regulate the transcription.
As stated before, epigenetic chromatin regulation
depends also on appropriate intranuclear positioning. Most
n u c l e a re v e n t sd on o to c c u rr a n d o m l yi nt h en u c l e o p l a s m ,
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territories, and the position of chromosomal region in
the nucleus inﬂuences its transcriptional activity. The
4q subtelomere is preferentially localized in the nuclear
periphery in both controls and FSHD patients [127, 128],
and this localization is evolutionary conserved [129]. In
FSHD1 cells, this localization depends on a sequence within
D4Z4 unit that tethers the subtelomere in the nuclear
periphery in a CTCF and Lamin-A-dependent manner
[130]. Although intranuclear positioning of 4q subtelomere
does not change during muscle diﬀerentiation, when several
epigenetic modiﬁcations take place [108], it has been shown
that the nuclear periphery localization in controls and
FSHD1 cells can be directed by diﬀerent sequences, proximal
or within D4Z4 repeat, respectively. This suggests that the
nuclear environment of FSHD locus in normal or aﬀected
subjects could be diﬀerent and could contribute to the
disease development [130].
In summary, the epigenetic analysis suggests that prob-
ably the presence of more than ten D4Z4 repeats provides
a physiological heterochromatization and repression of the
subtelomericregion,duetothesaturatinglevelsofepigenetic
repressors. In this view, less than ten D4Z4 repeats could
be considered as border line genotype, because the correct
heterochromatin formation is not ensured, determining a
predisposition to the disease and also explaining the high
variability in disease severity even in the same genetic
background. This hypothesis is reinforced by the evidence
that patients with less than 3 repeats have more chances
to develop FSHD1 disease and that asymptomatic carriers
of D4Z4 deletion are increasingly evident in FSHD [131].
Another complex issue about FSHD is the requirement for
at least one D4Z4 repeat for the development of the disease,
suggesting a gain of function eﬀect, where the presence of
an aberrant transcription of coding or noncoding RNA or
dysregulated binding of epigenetic factors recruited by the
D4Z4 array could be necessary for disease development.
Systematic analysis of epigenetic modiﬁcations across the
entire genome in FSHD1 and FSHD2 patients will be crucial
to dissect epigenetic mechanisms acting speciﬁcally on D4Z4
locus and involved in FSHD pathogenesis and progression.
6.Laminopathies
The nuclear scaﬀold (or nuclear matrix) is the network
of ﬁbers found inside a cell nucleus. The lamina is the
major component of nuclear matrix and is constituted by
a complex meshwork of proteins closely associated with
the inner nuclear membrane [132]. In vertebrates, lamins
have been divided into A and B types, based on sequence
homologies. All A-type lamins, A, C, C2, and Δ10, are
encoded by alternative splicing of a single gene (LMNA)
while two major mammalian B-type lamins, B1 and B2, are
encoded by diﬀerent genes (LMNB1 and LMNB2) [133]. All
major lamins terminate with a CAAX-box that is involved
in numerous posttranslational modiﬁcations including the
farnesylation of the cysteine, removal of the-AAX, and car-
boxymethylation of the cysteine [134]. These modiﬁcations
are thought to be important for the eﬃcient targeting of
the lamins to the inner nuclear membrane [135]. Moreover,
Lamin A is further processed by the zinc metalloproteinase,
Zmpste24/FACE1, which catalyzes the removal of additional
15 residues from Lamin A C-terminus including the far-
nesylated and carboxymethylated cysteine [136]. Expression
of the A- and B-type lamins is developmentally regulated
in mammals, resulting in cell type-speciﬁc complements
of lamins [137]. In the last years, genome wide studies
describinglaminboundchromosomalregionswerefocalized
speciﬁcally on B-type [138, 139]. However, it is becoming
increasingly evident that A-type lamins are scaﬀolds for
proteins that regulate DNA synthesis, responses to DNA
damage, chromatin organization, gene transcription, cell
cycle progression, cell diﬀerentiation, cancer invasiveness,
and epigenetic regulation of chromatin [140–143]. In line
with this observation, lamin distribution in the nucleus is
type speciﬁc, with Lamin B being predominantly present
at inner nuclear membrane and Lamin A also present in
lower concentrations, throughout the nucleoplasm [144],
suggesting, for the latter, a role beyond the maintenance
of mechanical stability of the nucleus. Genetic studies
conﬁrmed this hypothesis, showing that A- or B-type lamin
mutationshavediﬀerentimpactsonorganisms.Mutationsin
genes encoding B-type lamins are not frequently connected
to diseases in human and Lamin B1 null mice die during
early postnatal life with severe defects in their lung and
bones [145] while mice lacking Lamin B2 die shortly after
birth with severe brain abnormalities. Taken together, these
ﬁndings indicate that B-type lamins play a structural role
in the nucleus essential for cell and tissue function. On
the other hand, mice lacking A-type lamins have apparently
normal embryonic development [146], but postnatal growth
is delayed and they develop abnormalities of cardiac and
skeletal muscle. This is in line with studies in human,
where a large number of mutations of Lamin A/C (LMNA)
were found, causing a wide range of human disorders,
including lipodystrophy, neuropathies, autosomal dominant
Emery-Dreifuss muscular dystrophy (EDMD), and progeria.
The latter includes Hutchinson-Gilford progeria syndrome
(HGPS), atypical Werner syndrome, restrictive dermopathy,
andmandibuloacraldysplasiatypeA(MADA)[147].Collec-
tively, these degenerative disorders with a wide spectrum of
clinical phenotypes are known as the laminopathies. To date,
despite the identiﬁcation of several mutations on Lamin A
causing these disorders, it is diﬃcult to correlate phenotype
to genotype in laminopathies. It is still unclear how speciﬁc
mutations result in a particular tissue-speciﬁc laminopathy
phenotype [148] or why a single mutation in Lamin A gene
can result in diﬀerent phenotypes [149]. This suggests an
involvement of the individual epigenetic background to the
disease. Studies in HGPS cells conﬁrmed this hypothesis
ﬁnding several epigenetic alterations. In particular there
has been shown a decrease of the heterochromatin mark
H3K9me3 in pericentric regions and a downregulation of
the PRC2 component EZH2, accompanied by a loss of
H3K27me3 on the inactive X chromosome (Xi), which
leads to some decondensation of the Xi [150]. Notably,
it is not clear if observed epigenetic defects are cause or
consequence of the irreversible cascade of cellular mecha-6 Comparative and Functional Genomics
nisms dysfunction accompanying HGPS progression. Most
inherited LMNA mutations in humans cause disorders
that selectively aﬀect striated muscle, determining decreased
levels of A-type lamins. This was conﬁrmed in the Lmna null
mice, which develop abnormalities of cardiac and skeletal
muscle reminiscent of those seen in human subjects [146].
Remarkably, in humans, decreased lamin A levels observed
insomelaminopathiescouldalsobedependentondominant
negative eﬀect caused by an aberrant form of Lamin A.
Indeed, overexpression in transgenic mice of a human
lamin A variant responsible for Emery-Dreifuss muscular
dystrophy determines severe heart damage [151]. Several
hypotheses have been proposed to explain molecular mech-
anisms underlying muscular dystrophies caused by lamin A
mutations. The current model suggests that the prolonged
exposure to mechanical stress of muscle cells determines
the tissue-speciﬁc degeneration observed in laminopathies.
This model takes into consideration only the structural
role of lamin A, neglecting its functional role in chromatin
organization and gene expression control. There is a growing
body of evidence indicating that several signalling pathways,
suchaspRb,MyoD,Wnt-β catenin,andTGF-β,arealteredin
laminopathies [152, 153]. The Rb-MyoD-crosstalk is one of
themostdescribedpathwaysalteredinlaminopathies.MyoD
is a master transcription factor of muscle diﬀerentiation that
activates muscle-speciﬁc genes. Its levels are modulated by
dephosphorilated pRb, which takes part in the acetylation
and expression of MyoD [154]. Lamin A controls Rb levels
favouring its dephosphorilation [155]. Thus in the absence
of Lamin A the level of hypophosphorilated Rb and conse-
quently the level of MyoD are reduced, determining a defect
in muscle cells’ diﬀerentiation [156]. This was conﬁrmed by
a decreased number of MyoD positive nuclei observed in
skeletal muscle from laminopathy patients [157]. Given its
role in muscle-speciﬁc genes regulation, PcG protein could
be involved in aberrant gene expression observed in lamin
A defective background. Several indirect evidences support
this hypothesis indicating a potential crosstalk between PcG
proteins and Lamin A. As mentioned previously the nuclear
positioning of the PcG-regulated FSHD locus, responsible
for the described neuromuscular disorder, is altered in
human Lamin A/C null cells [127]. However, while the role
of PcG proteins in governing local chromatin higher-order
structures was extensively addressed [44, 47, 49], it is still
unknown if they also control the chromosomal position in
the nucleus and if the peripheral localization of FSHD is
dependent on PcG proteins. Recently, it has been suggested
that nuclear position of PcG proteins could be crucial
for muscle diﬀerentiation [158]. In this work, Wang and
colleagues have shown that the localization of PRC2 complex
at the nuclear periphery is mediated by the myogenic
regulator, Msx1, and is required for a correct repression
of Msx1 target genes. This localization occurs in myoblasts
and is necessary for a proper muscle diﬀerentiation [158].
The importance of chromatin architecture dynamics during
muscle diﬀerentiation was further conﬁrmed by studies per-
formed by Mattout et al. in C. elegans [159]. Using ablation
of the unique lamin gene in worm they found that lamin
is necessary for perinuclear positioning of heterochromatin.
Then, to test the physiological relevance of this association in
developing animals, they monitored tissue-speciﬁc changes
in nuclear position of speciﬁc genomic regions in worms
that express a dominant mutant form of lamin, which
mimics the human Emery-Dreifuss muscular dystrophy.
They found that in lamin defective background, muscle-
speciﬁc genes are not able to relocalize from the nuclear
periphery to a more internal location and this determines
loss of muscle integrity. Although there has been extensively
shown the crucial role of Polycomb proteins in mediating
nuclearchromatinarchitecture,todatenoevidencesupports
a direct involvement of PcG in muscle genes relocalization
during normal diﬀerentiation. Further studies are needed to
determine if physiological epigenetic dynamics that ensure a
correctmyogenesisarealteredinlamindefectivebackground
and the role of Polycomb proteins in this process.
7. Conclusions
In the last years the study of the epigenome and its role
in human disease progression has attracted considerable
interest. The insurgence of epigenetic deregulation in human
pathologies suggests that speciﬁc diseases might beneﬁt
from epigenetic-targeted therapies and this type of drug
therapy is becoming a reality in clinical settings [160, 161].
Notably, epigenetic variation could arise as a consequence
of the disease. Distinguishing epigenetic variations causing
or contributing to the disease process is not straightforward
but is nevertheless crucial to elucidate the functional role of
the disease-associated epigenetic variation and to optimize
their utility in terms of diagnostics or therapeutics. Recent
advances in genomic technologies, by the expanding use
of next-generation DNA sequencing (ChIP-seq) to assess
the genomic distribution of histone modiﬁcations, histone
variants, DNA methylation, and epigenetic factors, will
be helpful to study human disease-associated epigenetic
variation at genomewide level. Combined with appropriate
statistical and bioinformatic tools [162], these methods will
give us a more complete picture of all the loci that are
epigeneticallyaltered,althoughtheywillnotresolvethecause
or consequence issue. Then, the functional characterization of
the variety of epigenetic modiﬁcations at speciﬁc loci could
provide insight into the function of these modiﬁcations in
normal development and in subsequent transition to disease
states. These studies could ultimately lead to the future
development of more eﬀective epigenetic-based therapies,
although treatment with these classes of drugs should be
carefully examined to determine whether the therapeutic
beneﬁts outweigh the potential adverse eﬀects [163, 164].
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